**Supplementary Table 1. Baseline demographics, disease characteristics, HBV serological status, conditioning regimen, CAR-T cell dose, response and toxicity after CAR-T cell therapy, and duration of follow-up for HBV reactivation in each patient**



Pt, patient; F, female; M, male; ECOG, Eastern Cooperative Oncology Group; DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; HD NHL, high-grade non-Hodgkin lymphoma; ALL, acute lymphoblastic leukemia; HSCT, hematopoietic stem cell transplantation; Y, yes; N, no; FC: fludarabine/cyclophosphamide; C: cyclophosphamide; CR: complete remission; PR: partial remission; SD: stable disease; NR: no response. CRS, cytokine release syndrome; ICANS: immune effector cell-associated neurotoxicity syndrome.

\*, indicates the patients with HBV reactivation post CAR-T cell therapy